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Short Report Labelled drug-related public expenditure in 
relation to gross domestic product (gdp) in Europe: 
A luxury good?
Luis Prieto1,2
Abstract
"Labelled drug-related public expenditure" is the direct expenditure explicitly labelled as related to illicit drugs by the 
general government of the state. As part of the reporting exercise corresponding to 2005, the European Monitoring 
Centre for Drugs and Drug Addiction's network of national focal points set up in the 27 European Union (EU) Member 
States, Norway, and the candidates countries to the EU, were requested to identify labelled drug-related public 
expenditure, at the country level. This was reported by 10 countries categorised according to the functions of 
government, amounting to a total of EUR 2.17 billion. Overall, the highest proportion of this total came within the 
government functions of Health (66%), and Public Order and Safety (POS) (20%). By country, the average share of GDP 
was 0.023% for Health, and 0.013% for POS. However, these shares varied considerably across countries, ranging from 
0.00033% in Slovakia, up to 0.053% of GDP in Ireland in the case of Health, and from 0.003% in Portugal, to 0.02% in the 
UK, in the case of POS; almost a 161-fold difference between the highest and the lowest countries for Health, and a 6-
fold difference for POS. Why do Ireland and the UK spend so much in Health and POS, or Slovakia and Portugal so little, 
in GDP terms? To respond to this question and to make a comprehensive assessment of drug-related public 
expenditure across countries, this study compared Health and POS spending and GDP in the 10 reporting countries. 
Results found suggest GDP to be a major determinant of the Health and POS drug-related public expenditures of a 
country. Labelled drug-related public expenditure showed a positive association with the GDP across the countries 
considered: r = 0.81 in the case of Health, and r = 0.91 for POS. The percentage change in Health and POS expenditures 
due to a one percent increase in GDP (the income elasticity of demand) was estimated to be 1.78% and 1.23% 
respectively. Being highly income elastic, Health and POS expenditures can be considered luxury goods; as a nation 
becomes wealthier it openly spends proportionately more on drug-related health and public order and safety 
interventions.
Findings
Producing estimates of drug-related public expenditure
was one of the many targets set by the former (2005-08)
European Union's (EU) drugs action plan [1]. In this light,
the European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) [2] launched in July 2008 a publi-
cation focusing on Drug-related public expenditure in
Europe [2]. Testing a new methodology of combining
'labelled' and 'unlabelled' expenditure, the report pre-
sented estimates of how much European governments
spent in 2005 on the drugs problem.
'Labelled drug-related expenditures' are defined as the
direct ex-ante planned spending that reflects the volun-
tary engagement of the state in the field of illicit drugs.
Direct public expenditures explicitly labelled as 'drug-
related' can be easily traced back by exhaustively review-
ing official accountancy documents such as national bud-
g e t s  a n d  y e a r - e n d  r e p o r t s .  T h e  n a t i o n a l  b u d g e t  i s  a
comprehensive document, encompassing all government
revenue and expenditure, so that the necessary trade-offs
between different policy options can be assessed. The
government's draft budget is submitted to the national
parliament for review and approval prior to the start of
the fiscal year. The final approved budget, and related
documents, include a detailed description of each reve-
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nue and expenditure programme (i.e. the particular pur-
pose). Expenditures are commonly classified by
administrative unit (e.g., ministry, agency), but supple-
mentary information by economic and/or functional cat-
egories are usually presented as well. The year-end report
is the government's key accountability document. It is
audited by the supreme audit institution and released
within a defined period of the end of the fiscal year. The
year-end report shows compliance with the level of reve-
nue and expenditures authorised by Parliament in the
budget. Any in-year adjustments to the original budget
should be shown separately. The presentation format of
the year-end report mirrors the presentation format of
the budget (although sometimes in a more aggregated
form).
'Unlabelled expenditure' refers to unplanned spending
and was estimated through modelling techniques, based
on a top-down budgetary procedure. Starting from over-
all aggregated expenditures, this procedure estimates the
proportion causally attributable to drug use (Unlabelled
Drug-related Expenditure = Overall Expenditure ×
Attributable Proportion). For example, to estimate the
prison drug-related expenditures in a given country, two
elements would be necessary: the overall prison expendi-
tures in the country for a given fiscal year, and the attrib-
utable proportion of inmates due to drug-related issues.
The product of the two will give a rough estimate that can
be compared across different countries.
This twofold approach aimed to provide more compre-
hensive and accurate estimates of public spending in
tackling drugs and drug addiction Europe-wide. While
f i g u r e s  s h o u l d  b e  u s e d  w i t h  c a u t i o n ,  e s t i m a t e s  f r o m
reporting countries, extrapolated to European level,
arrived at a total cost of drug-related public expenditure
in 2005 of EUR 34 billion (labelled and unlabelled). This
represents an average expenditure of EUR 60 per Euro-
pean citizen per year [2].
Of the total cost identified, only 7% (EUR 2.42 billion)
was labelled expenditure [2]. This is somewhat paradoxi-
cal because from a drug policy perspective labelled
expenditure is more relevant than unlabelled expendi-
ture; labelled expenditure is proactive, in that it is linked
to the achievement of specific policy aims, while unla-
belled expenditure is reactive, in that it arises as a result
of drug misuse, such as enforcement or health costs [3].
In any case, as discussed by Reuter [4], the "drug budget"
(i.e. labelled expenditure) aimed at reducing drug use and
related problems is a useful description of a nation's drug
policy. Cross-country comparisons of their levels and
composition can certainly be of use to policy decision
makers.
The main challenge of comparing budget expenditure
for international benchmarking across countries is con-
sistency of reporting. In this respect, ten countries
(Czech Republic, Ireland, France, Luxembourg, Hungary,
Poland, Portugal, Slovakia, Finland, and the United King-
dom) yield labelled expenditure classified according to a
common categorisation system: the international Classi-
fication of the Functions of Government (COFOG).
COFOG is a detailed classification of the socioeconomic
objectives that government units aim to achieve through
a range of outlays (e.g. health, education, social protec-
tion, public order and safety, among others) [5]. Overall,
of the total labelled expenditure categorised by these
countries, 86% (EUR 1.88 billion) came within two gov-
ernment functions: Health (66%) (i.e. medical products,
outpatient services, hospital services, public health ser-
vices, R&D) and Public Order and Safety (POS) (20%) (i.e.
police services, law courts, prisons) (Table S1, Additional
file 1). The rest of the expenditures (not considered in the
present report) went to General Public Services (5%),
Housing and Community Ammenities (1.71%) Education
(0.88%), Economic Affairs (0.62%), Social Protection
(0.61%), Defence (0.05%), or were not appropriately clas-
sified (4.20%) [2].
By country, the average share of GDP was 0.023% for
Health, and 0,013% for POS. However, these shares var-
ied considerably across countries, ranging from 0.00033%
in Slovakia, up to 0.053% of GDP in Ireland in the case of
Health, and from 0.003% in Portugal, to 0.02% in the UK,
in the case of POS; almost a 161-fold difference between
the highest and the lowest countries for Health, and a 6-
fold difference for POS (Table S1, Additional File 1). Why
do Ireland and the UK spend so much in Health and POS,
or Slovakia and Portugal so little, in GDP terms?
To respond to this question and to make a more com-
prehensive assessment of labelled drug-related public
expenditure across countries, this study described and
compared Health and POS spending per capita (response
variable/s) and GDP per capita (explanatory variable) in
the 10 reporting countries through linear regression anal-
ysis. All variables were transformed into natural logarith-
mic values to have them normally distributed and for
interpretability purposes. Expenditures and GDP were
expressed in 2005 Euro Purchasing Power Parity [6].
The results show the positive association between the
GDP per capita and Health and POS spending per capita
(Figures 1 and 2, respectively) across the 10 countries
analyzed (Figures 1 and 2, respectively). There is an over-
all clear tendency for countries with higher GDP to spend
a greater proportion of their GDP on Health (Pearson's r
= 0.81, n = 10, exact 2-side p = 0.0032), and POS (Pear-
son's r = 0.91, n = 6, exact 2-side p = 0.0653), suggesting
that GDP is an important determinant of labelled drug-
related public expenditure in a country. The percentage
change in Health and POS labelled expenditures per cap-
ita due to a one percent increase in GDP per capita (the
income elasticity of demand (IED)) was estimated to bePrieto Substance Abuse Treatment, Prevention, and Policy 2010, 5:9
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Figure 1 Labelled Drug-Related Expenditure (Health) and GPD per capita, in Europe (PPP EUR 2005).
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Figure 2 Labelled Drug-Related Expenditure (Public Order and Safety) and GPD per capita, in Europe (PPP EUR 2005).
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1.78% (R2 = 0.66, SEE = 1.56) and 1.23% (R2 = 0.82, SEE =
0.79) respectively. The IED indicates how sensitive is the
demand for a good to an income change [7]; if IED is
greater than one, demand for the item is considered to
have a high income elasticity. Luxury goods (e.g. jewels)
are said to have high income elasticity: as people become
w e a l t h i e r ,  t h e y  w i l l  b u y  m o r e  a n d  m o r e  o f  t h e  l u x u ry
good. In economics, a luxury good is any type of good for
which demand increases more than proportionally as
income rises [8]. In our case, being highly "income" elas-
tic, Health and POS expenditures can be considered lux-
ury goods; as a country becomes wealthier it spends
proportionately more on drug-related health and public
order and safety interventions.
The results confirm the importance of GDP as a deter-
minant of Health and POS spending, and suggest that this
effect is higher on POS than in Health; GDP accounted
for 82% of the variation in POS expenditure, and 66% of
the variation in Health.
The variations in overall health care expenditure and
GDP have already been extensively explored in the litera-
ture [9]. Earlier studies were based, like the present study,
on cross-sectional approaches for particular years
[10,11]. Other studies have relied on the analysis of
dynamic data, or time series panel data to determine the
relation between GDP and health care expenditure [12-
14]. Overall, results have confirmed the importance of
GDP as a determinant of health spending, with an esti-
mated income elasticity of demand above unity.
The present study suggests the confirmation of an intu-
itive expectation: the elements of economic wealth of a
nation and public investment in the problems of illicit
drugs are interdependent. This fact has important impli-
cations for policy making by forcing decision makers to
take budgetary effects into account when defining drug
strategies and action plans, something that currently is
not appropriately implemented in the EU.
Nevertheless, caution is needed when considering the
conclusions obtained from the results of the regression
analysis in this study; there are a series of limitations that
might preclude the conclusions reached.
First, labelled drug-related public expenditure is a com-
ponent of GDP, thus, all things being equal, an increase of
public drug-related expenditure will raise GDP by the
same amount. Under these circumstances, a positive cor-
relation can be expected between GDP and public expen-
diture on drugs, due to the fact that one variable includes
the other (part-whole correlation), even when there
would not be association between them.
Second, the calculations made in the study are based on
the assumption that drug-related public expenditure
depends on a country's GDP. Is this hypothesized causal
relationship plausible? The regression results found do
not necessarily establish a causal relationship between
GDP and public expenditure. Although the statistical
computations used to produce the estimated measure of
association are appropriate for descriptive purposes, the
estimate itself may be biased. Bias may result from not
considering in the analysis other variables that could
account for the observed association, such as the size of
the drug problem in the country, the political orientation
of government, or the model of state. The resulting biases
can distort the true value of the correlation coefficient
and lead to a false conclusion on the relationship between
the two variables involved in the analysis. Should this be
the case, a deeper assessment of the plausibility of the
causal relationship between GDP and labelled expendi-
ture must be performed.
Third, only 10 countries were included in the analysis.
Unfortunately, studies on public expenditure require a
significant amount of analytical work for the labelled
component, and require a certain degree of creativity as
far as non-labelled expenditure is concerned. Altogether,
this meant that comprehensive approaches to precisely
estimate public expenditure were beyond the technical,
r e s o u r c e  o r  h u m a n  c a p a b i l i t i e s  o f  s o m e  n a t i o n a l  f o c a l
points in the EU. The reporting countries cannot be con-
sidered a representative sample of the 27 EU member
states; thus, the results obtained are only applicable to the
countries analyzed, and no generalizations can be made
to the remaining countries. This situation should be
resolved over time by providing simple, clear and
straightforward guidelines on how to proceed in identify-
ing labelled and unlabelled expenditure across countries
in the EU. The EMCDDA can play a leading role in this
action by compiling the different strategies available for
identifying expenditure, based on the experiences
reported by the countries who have already carried out
this exercise.
Expansions of the analyses presented here can obvi-
ously be made by adding countries, by reflecting other
type of expenditures (e.g. private expenditures), by
including other explanatory variables in the model, and
by considering additional years of reference (e.g., panel
data). The result will be a greater insight into the under-
standing of differences in labelled drug-related public
expenditures in different countries. In addition, this
could help explain how they influence the quality and
quantity of drug-related interventions, and which of them
perform better in terms of cost-effectiveness.
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